Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Shanghai Fosun Pharmaceutical (Group) Co Shiller PE Ratio?
Shanghai Fosun Pharmaceutical (Group) CoSFOSF 72 Shiller PE Ratio is 15.71 as of Aug. 06, 2026, which is 41% below its 10-year median of 26.58. GuruFocus rates SFOSF with a GF Score™ of 72/100 and a GF Value™ of $2.62 (Modestly Undervalued). The stock has 10 warning signs investors should review. Among 535 Drug Manufacturers companies, Shanghai Fosun Pharmaceutical (Group) Co ranks better than 68.79% on this metric.
SFOSF's Shiller PE Ratio is ranked better than 68.79% of 535
companies
in the Drug Manufacturers industry
Industry Median: 25.04
vs SFOSF: 16.93
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.
Shanghai Fosun Pharmaceutical (Group) Co's adjusted earnings per share data for the three months ended in Mar. 2026 was $0.048. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $0.14 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Shanghai Fosun Pharmaceutical (Group) Co (OTCPK:SFOSF) Shiller PE Ratio Explanation
Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.
Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.
Be Aware
Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.
Shanghai Fosun Pharmaceutical (Group) Co Shiller PE Ratio Related Terms
Shanghai Fosun Pharmaceutical (Group) Co Shiller PE Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Fosun Pharmaceutical (Group) Co Shiller PE Ratio Chart
Shanghai Fosun Pharmaceutical (Group) Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Fosun Pharmaceutical (Group) Co's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Fosun Pharmaceutical (Group) Co Shiller PE Ratio vs Drug Manufacturers Industry
Shanghai Fosun Pharmaceutical (Group) Co Shiller PE Ratio Calculation
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Add all the adjusted EPS together and divide 10 will get our E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) has a Shiller PE Ratio of 15.71 as of Aug. 06, 2026. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Shanghai Fosun Pharmaceutical (Group) Co and its competitors. This is 41% below median its historical median of 26.58. Over the past decade, Shanghai Fosun Pharmaceutical (Group) Co's Shiller PE Ratio has ranged from 15.83 to 68.81. According to the industry distribution chart, Shanghai Fosun Pharmaceutical (Group) Co ranks #167 out of 535 companies in the Drug Manufacturers industry, placing it in the top 31.2%.
Is Shanghai Fosun Pharmaceutical (Group) Co's Shiller PE Ratio too high?
Shanghai Fosun Pharmaceutical (Group) Co's current Shiller PE Ratio of 15.71 is 41% below median its 10-year median of 26.58. Over the past 10 years, this metric has ranged from a low of 15.83 to a high of 68.81. The Drug Manufacturers industry median Shiller PE Ratio is 25.04. Shanghai Fosun Pharmaceutical (Group) Co's value of 15.71 is 37.3% below this industry median. Based on the distribution chart, Shanghai Fosun Pharmaceutical (Group) Co ranks #167 out of 535 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Shanghai Fosun Pharmaceutical (Group) Co has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Fosun Pharmaceutical (Group) Co's Shiller PE Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shanghai Fosun Pharmaceutical (Group) Co ranks #167 out of 535 companies for Shiller PE Ratio. This puts Shanghai Fosun Pharmaceutical (Group) Co in the upper half of its industry. The industry median Shiller PE Ratio is 25.04. Shanghai Fosun Pharmaceutical (Group) Co's value of 15.71 is 37.3% below this benchmark. Historically, Shanghai Fosun Pharmaceutical (Group) Co's own Shiller PE Ratio has ranged from 15.83 to 68.81 over the past decade. While the company's 10-year median is 26.58 vs. the industry median of 25.04, Shanghai Fosun Pharmaceutical (Group) Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shiller PE Ratio for a Drug Manufacturers company?
The median Shiller PE Ratio among Drug Manufacturers companies is 25.04, based on 535 companies in the industry. Companies in the top quartile (top 25%) have a Shiller PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Shiller PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Fosun Pharmaceutical (Group) Co's current Shiller PE Ratio of 15.71 is 37.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shiller PE Ratio mean?
A high Shiller PE Ratio can signal that a stock is expensive relative to its fundamentals. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Shanghai Fosun Pharmaceutical (Group) Co and its competitors. For the Drug Manufacturers industry, the median Shiller PE Ratio is 25.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Fosun Pharmaceutical (Group) Co's current Shiller PE Ratio is 15.71, which is 41% below median its own 10-year median of 26.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Fosun Pharmaceutical (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.62, compared to a current price of $2.20 — trading 16% below its estimated fair value. The current Shiller PE Ratio is 15.71, which is 41% below median its 10-year median of 26.58 and 37.3% below the Drug Manufacturers industry median of 25.04. Shanghai Fosun Pharmaceutical (Group) Co's overall GF Score™ is 72/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shiller PE Ratio calculated?
Shiller PE Ratio is calculated from a company's financial statements. For Shanghai Fosun Pharmaceutical (Group) Co (SFOSF), the current Shiller PE Ratio is 15.71 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co stock appears to be undervalued.
The current stock price of $2.20 is trading 16% below its estimated GF Value™ of $2.62.
GuruFocus considers Shanghai Fosun Pharmaceutical (Group) Co to be Modestly Undervalued.
Key valuation signals for SFOSF:
Shiller PE Ratio: 15.71 (41% below median its 10-year median of 26.58)
GF Value™: $2.62 vs. price of $2.20 (16% below fair value)
Industry Position: 37.3% below the Drug Manufacturers median (#167 of 535)
No single metric tells the full story. See the SFOSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Fosun Pharmaceutical (Group) Co Ltd is engaged in the development, manufacture, sale of pharmaceutical products and medical equipment, the import and export of medical equipment, and the provision of related and other consulting services and investment management. Its business segments are Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. It generates the majority of its revenue from the Pharmaceutical manufacturing segment. The company considers mergers and acquisitions as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities. Its geographic areas are the Chinese mainland, Regions outside the Chinese mainland, and other countries.
72GF Score
Get the complete analysis for SFOSF
Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SFOSF has been successfully added to your 
